Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 1 to 3 of 3 results for nonacog beta pegol

  1. Marstacimab for treating severe haemophilia A or severe haemophilia B in people 12 years and over [ID6342]

    In development [GID-TA11397] Expected publication date: 26 February 2025

    Technology appraisal guidance
    In development

  2. Fidanacogene elaparvovec for treating moderately severe to severe haemophilia B [ID4032]

    In development [GID-TA11117] Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. Etranacogene dezaparvovec for treating moderately severe or severe haemophilia B (TA989)

    Evidence-based recommendations on etranacogene dezaparvovec (Hemgenix) for treating moderately severe or severe haemophilia B in adults.

    Technology appraisal guidance
    Published
    24 July 2024

    Sections for TA989